This Library Guide (LibGuide) is a collection of useful documents & evidence on the pentavalent meningococcal ACWYX conjugate vaccine (Men5CV) which was prequalified by the World Health Organization (WHO) in July 2023.
This vaccine should not be confused with the Pentavalent Meningococcal ABCWY vaccine which is currently used mainly in high income countries especially where Serogroup B is prevalent.
The WHO's "Defeating Meningitis by 2030" global roadmap aims to eliminate bacterial meningitis epidemics, reduce cases of vaccine-preventable bacterial meningitis by 50% and deaths by 70%, and improve quality of life for those affected by meningitis.
The prequalification of the novel pentavalent ACWYX (Men5CV) vaccine by the WHO, and subsequent recommendation for incorporation into routine immunization programs has the potential to eradicate meningitis.
Men5CV is a vaccine that protects against five strains of meningococcal bacteria, specifically serogroups A, C, W, and Y, and also serogroup X. Nigeria was the first country to roll out the new Men5CV vaccines.
In world first, Nigeria introduces new 5-in-1 vaccine against meningitis
https://www.who.int/news/item/12-04-2024-in-world-first--nigeria-introduces-new-5-in-1-vaccine-against-meningitis
The LibGuide supports NITAG members and other policy makers in Africa with making evidence-based recommendations on incorporation of the pentavalent meningococcal ACWYX conjugate vaccine (Men5CV) into EPI.
This LibGuide has been compiled by Dilshaad Brey. Please email dilshaad.brey@uct.ac.za for any queries or to request the full text of articles marked 'Not OA' - not open access.